

MANUSCRIPT TITLE:

Inhaled corticosteroids downregulate SARS-CoV-2-related gene expression in COPD: results from a RCT

AUTHORS:

Stephen Milne^{1,2,3*}, Xuan Li^{1*}, Chen Xi Yang¹, Ana I Hernandez Cordero¹, Fernando Sergio Leitao Filho^{1,2}, Cheng Wei Tony Yang^{1,4}, Tawimas Shaipanich², Stephan F van Eeden^{1,2}, Janice M Leung^{1,2}, Stephen Lam^{2,5}, Don D Sin^{1,2}

1. University of British Columbia Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, British Columbia, Canada
2. University of British Columbia Division of Respiratory Medicine, Vancouver, British Columbia, Canada
3. University of Sydney Faculty of Medicine and Health Sciences, Sydney, New South Wales, Australia
4. Providence Health Care Providence Airway Centre, Vancouver, British Columbia, Canada
5. BC Cancer Research Centre Department of Integrative Oncology, Vancouver, British Columbia, Canada

*authors made equal contributions to the work

CORRESPONDING AUTHOR:

Dr Stephen Milne

UBC Centre for Heart Lung Innovation

Rm 166 – St Paul’s Hospital

1081 Burrard Street

Vancouver V6Z 1Y6

British Columbia, Canada

T: +1-604-806-8346

E: Stephen.milne@hli.ubc.ca

AUTHOR CONTRIBUTIONS:

Data acquisition: SM, FSSLF, TS, SFVE, JML, SL, DDS

Data analysis and interpretation: SM, XL, CXY, AIHC, FSSLF, CWTY, JML, DDS

Drafting of manuscript: SM, XL

Critical revision of draft manuscript: SM, XL, CXY, AIHC, FSSLF, CWTY, SFVE,
JML, SL, DDS

All authors reviewed and approved the final version of the manuscript.

All authors agree to be accountable for all aspects of the work including data
integrity.

FINANCIAL SUPPORT:

The DISARM study was funded by an investigator-initiated grant from AstraZeneca.

SM and AIHC are supported by the MITACS Accelerate Program.

ONLINE SUPPLEMENTARY MATERIAL:

This article has an online data supplement.

DATA SHARING STATEMENT:

Requests for data sharing should be made directly to the Principal Investigator, Dr.

Don Sin (don.sin@hli.ubc.ca).

ABSTRACT:

Rationale: Chronic obstructive pulmonary disease (COPD) is a risk factor for severe COVID-19. Inhaled corticosteroids (ICS) are commonly prescribed for the prevention of acute exacerbations in people with COPD, but their use is associated with increased risk of respiratory infections. The effects of ICS on SARS-CoV-2 susceptibility or COVID-19 severity are currently unknown.

Objectives: To determine the effects of ICS treatment on the bronchial epithelial cell expression of key SARS-CoV-2-related genes in volunteers with COPD.

Methods: We performed a randomized, open-label, parallel treatment trial of 12 weeks treatment with ICS in combination with long-acting beta-agonist (formoterol/budesonide 12/400 µg twice daily or salmeterol/fluticasone propionate 25/250 µg twice daily), or treatment with LABA only (formoterol 12 µg twice daily), in volunteers with mild to very severe COPD. We obtained bronchial epithelial cell samples via bronchoscopy before and after treatment, and determined transcriptome-wide gene expression by RNA sequencing.

Main Results: 63 volunteers were randomized to receive treatment. Compared to formoterol alone, formoterol/budesonide treatment decreased the expression of the SARS-CoV-2 receptor gene *ACE2* and the host cell protease gene *ADAM17*. These genes were highly co-expressed with innate immune response genes, particularly those of the type I interferon and anti-viral response pathways, which also tended to decrease following ICS treatment.

Conclusions: This is the first randomized controlled trial to show that ICS affect the expression of key SARS-CoV-2-related genes in COPD. Their relation to important anti-viral response genes may have critical implications for SARS-CoV-2 susceptibility or COVID-19 severity in this vulnerable population.

KEY WORDS:

Chronic obstructive pulmonary disease, COVID-19, transcriptomics, airway

epithelium

Introduction

COVID-19, which is caused by infection with the SARS-CoV-2 virus, exhibits a broad spectrum of severity ranging from asymptomatic to severe pneumonia and death. Observational studies show that chronic obstructive pulmonary disease (COPD) is associated with increased risk of severe COVID-19 and mortality (1), the underlying biological mechanisms of which are currently unclear.

Inhaled corticosteroids (ICS) are commonly prescribed as maintenance therapy in COPD. Despite their clinical efficacy in a subset of patients, ICS have been associated with increased risk of bacterial pneumonia in COPD (2) and impaired immune response to viruses *in vitro* (3). There is currently no epidemiological evidence that ICS treatment modifies COVID-19 susceptibility or the severity of infection in COPD patients (4, 5). However, there is poor understanding of how ICS medications affect cellular processes relevant to SARS-CoV-2 biology.

We previously demonstrated that COPD is associated with increased expression of angiotensin-converting enzyme 2 (*ACE2*), the gene encoding the SARS-CoV-2 receptor, in human lungs (6, 7). Recent *in vitro* studies suggest that ICS may downregulate *ACE2* at the gene and protein level (8). This is supported by observational data in both COPD and asthma patients, where ICS use was associated with decreased *ACE2* mRNA in sputum (8, 9). However, the effects of ICS on genes related to SARS-CoV-2 infection and the subsequent host response have not been examined in prospective interventional studies.

In this study, we measured gene expression in lower airway bronchial epithelial cells (BEC) to determine if ICS treatment alters the expression of SARS-CoV-2-related genes (including cell surface receptors, proteases, and innate immune response genes) as part of a randomized controlled trial (RCT) in COPD. We collected the BEC specimens before and after 12 weeks of treatment with long-acting beta-2 adrenoceptor agonist (LABA)/ICS combination therapy or LABA monotherapy. ICS treatment led to relative downregulation of the SARS-CoV-2 receptor gene *ACE2* and the host cell protease gene *ADAM17*. These genes were highly connected to anti-viral, innate immune response genes, which may have implications for COVID-19 severity in this vulnerable population.

Results

Characteristics of participants in the DISARM trial

In the DISARM study (clinicaltrials.gov identifier NCT02833480), we randomized 63 subjects with mild to very severe COPD to receive LABA monotherapy with formoterol (FOR), or LABA/ICS combination therapy with formoterol/budesonide (FOR/BUD) or salmeterol/fluticasone (SAL/FLU), for 12 weeks (Figure 1). Bronchial brush samples were collected from 6-8th generation airways via bronchoscopy before and at the end of treatment. The majority of participants were male and had moderate to severe airflow obstruction (Table 1).

ICS treatment downregulates key SARS-CoV-2 related genes in COPD

In order to quantify BEC gene expression, we performed whole-transcriptome RNA sequencing (RNA-seq) on bronchial brush samples. After quality control filtering, a total of 15,263 genes were included in the expression dataset. We examined the expression levels of key SARS-CoV-2-related genes: *ACE2* (encodes the putative SARS-CoV-2 entry receptor ACE2) (10); *BSG* (encodes an alternative entry receptor basigin, also known as CD147) (11); *TMPRSS2* (encodes a cell surface metalloproteinase that primes the SARS-CoV-2 spike protein to facilitate viral entry) (10); *ADAM17* (encodes a metalloproteinase that cleaves the ACE2 protein and facilitates endocytosis of the ACE2-SARS-CoV-2 complex) (12); and *FURIN* (encodes the subtilisin-like peptidase furin, which can prime the SARS-CoV-2 spike protein) (13, 14).

Sixty one participants had pre-treatment gene expression data available. There were no obvious differences in overall gene expression between the treatment groups at baseline (Figure E1). Each of the key SARS-CoV-2-related genes were expressed in pre-treatment BECs (Figure 2A). Pre-treatment *ACE2* and *BSG* expression were negatively associated with age ($p=3.4 \times 10^{-4}$ and $p=0.033$, respectively; Figure 2B). Compared to ex-smokers, current smokers had significantly greater pre-treatment expression of *ACE2* ($p=9.3 \times 10^{-5}$), *BSG* ($p=4.8 \times 10^{-4}$) and *TMPRSS2* ($p=0.028$) (Figure 2C).

Fifty four participants had both pre- and post-treatment gene expression data available. Compared to baseline levels, LABA-only treatment with FOR significantly increased expression of *ACE2* (median $\Delta \log_2 \text{CPM} +0.47$, $p=0.002$) and *ADAM17*

(median $\Delta\log_2\text{CPM}$ +0.13, $p=0.03$). LABA/ICS combination treatment with FOR/BUD significantly decreased *ADAM17* expression (median $\Delta\log_2\text{CPM}$ -0.19, $p=0.003$), while treatment with SAL/FLU did not significantly alter expression of any of the key genes (Table E1, Figure E2).

A placebo arm was not included in the DISARM trial as this could predispose participants to a worsening of their COPD symptoms or acute exacerbation. However, we were able to isolate the effects of ICS therapy by comparing the pre- to post-treatment changes in each of the LABA/ICS groups to the LABA-only group. $\Delta\log_2\text{CPM}$ *ACE2* for FOR/BUD and SAL/FLU groups were significantly lower than that of the FOR group ($p=0.049$ and $p=0.03$, respectively), while $\Delta\log_2\text{CPM}$ *ADAM17* for FOR/BUD was significantly lower than that of the FOR group ($p=7.05\times 10^{-5}$) (Figure 3). These results indicate that ICS have a suppressive effect on the transcription of these genes.

Transcriptome-wide effects of ICS treatment in COPD

Corticosteroids have pleiotropic effects on gene expression, including positive and negative regulation of transcription (15). We therefore wanted to explore the effects of treatment on the whole transcriptome. After a gene selection process based on pairwise comparisons of $\Delta\log_2\text{CPM}$ between treatment groups (see Methods Supplement), a total of 1,188 genes were plotted in a clustered heat map (Figure 4). Overall, the changes in gene expression were modest, with the majority of genes having median $\Delta\log_2\text{CPM}$ within a range of ± 1 . In the LABA/ICS treatment groups, the direction of effect was evenly split between upregulation (i.e. $\Delta\log_2\text{CPM} > 0$) and

downregulation (i.e. $\Delta\log_2\text{CPM} < 0$). Individual genes tended to show opposite effects between the LABA-only and LABA/ICS treatment arms such that genes upregulated by FOR treatment were downregulated by FOR/BUD and SAL/FLU treatment and vice versa. Changes were mostly consistent between the FOR/BUD and SAL/FLU groups, suggestive of an ICS class effect.

SARS-CoV-2-related genes are co-expressed with innate immune response genes

Co-expression of genes (i.e. correlation between their transcriptional levels) can provide insights into the biological functions of genes that are 'active' at the same time (16). We therefore determined genes that were co-expressed with each of the key SARS-CoV-2-related genes in the pre-treatment expression data by performing a weighted gene correlation network analysis (WGCNA) (17, 18). The key SARS-CoV-2-related genes were contained within three of the 20 co-expression modules identified (Figure 5, Tables E2-E4). *ACE2* was in a module of 538 genes; its 'hub gene' (i.e. the gene with the strongest correlation to the module eigengene or 'module membership') was *DDX58* (DEXD/H-box helicase 58), which encodes a protein that is involved in viral dsRNA recognition. *BSG* and *TMPRSS2* were found within a module of 1,528 genes, with the hub gene *AASDHPPT* (aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase), which encodes a protein involved in amino acid metabolism. *ADAM17* and *FURIN* were found in a module of 2,091 genes with the hub gene *GNA13* (G-protein subunit alpha-13), which encodes a component of G-proteins that are involved in transmembrane signal transduction.

To functionally characterize each of the relevant gene modules, we examined the overlap of module membership with Gene Ontology (GO) biological processes (19) at a false discovery rate <0.05 (Figure 6, Tables E5-E7). The *ACE2* module was highly enriched for genes related to type I interferon (IFN-I) production and response, the response to interferon-gamma, and the response to viruses in general. The *ADAM17/FURIN* module was enriched for genes related to the regulation of innate immunity, leukocyte function (including T cell activation and myeloid cell differentiation) and cytokine production. The *BSG/TMPRSS2* module was enriched for genes related to cellular processes such as protein transmembrane transport, peroxisome organization, and nucleic acid processing.

We next examined the enrichment of the modules with genes in human disease pathways using the Kyoto Encyclopedia of Genes and Genomes (KEGG) (20) (Figure E3, Table E8-E10). The *ACE2* module was enriched for genes in KEGG pathways related to viral infections (including influenza A, measles, Epstein-Barr virus, and herpes simplex virus) and immune-mediated diseases (including primary immunodeficiency, allograft rejection, and type 1 diabetes mellitus). The *ADAM17/FURIN* module was enriched for genes related to infectious diseases (including leishmaniasis, *Staphylococcus aureus* infection, and tuberculosis), as well as autoimmune diseases (including rheumatoid arthritis and inflammatory bowel disease). The *BSG/TMPRSS2* module was not enriched for any KEGG pathways related to human disease at FDR <0.05 .

Together, these results show that the SARS-CoV-2 receptor gene *ACE2* and the host cell protease genes *ADAM17* and *FURIN* are highly connected to genes of the

immune system, particularly those related to the innate immune response to viral infection.

Genes co-expressed with SARS-CoV-2-related genes are downregulated by ICS treatment

To further explore how ICS treatment affects SARS-CoV-2-related genes, we annotated genes in the heatmap that belonged to each of the three SARS-CoV-2-related gene co-expression modules (Figure 4); 42 percent of the genes in the heatmap belonged to one of the SARS-CoV-2-related gene modules. The *ADAM17/FURIN* module was over-represented in the heatmap (32 percent of mapped genes) compared to the *ACE2* module (4 percent of mapped genes) and *BSG/TMPRSS2* module (6 percent of mapped genes). *ADAM17/FURIN* and *ACE2* module genes were clustered in areas of the heatmap characterized by genes whose expression was downregulated by LABA/ICS.

Changes in SARS-CoV-2-related gene expression are associated with changes in innate immune response genes

ICS have been shown to alter the expression of innate immune response pathways, including key anti-viral response genes and pro-inflammatory cytokines (3, 15, 21, 22). To further explore how ICS affect these pathways, we examined pre- to post-treatment changes in expression of a panel of genes encompassing virus recognition, IFN-I/III signaling, and inflammatory cytokines/chemokines (Figure 7A). At FDR<0.05, FOR/BUD treatment significantly reduced the expression of 8 genes in

the panel (*IL10RA*, *IRF3/8*, *IL1B*, *IL1R2*, *CCL3/5* and *CXCL8*), while SAL/FLU reduced the expression of a single gene (*CCL5*). We then examined how changes in the key SARS-CoV-2 genes were related to changes in these immune response genes using Pearson correlation (Figure 7B, Figure E4, Table E11). Notably, changes in *ACE2* expression were correlated with changes in the expression of viral sensor genes (e.g. *DDX58*, *TLR3*), IFN-I/III signal transducers (e.g. *JAK2*, *STAT1/2*, *IRF9*) and interferon-stimulated genes (ISGs) (e.g. *OAS2/3*, *CXCL10*, *RSAD2* and *EIF2AK2*) but not inflammatory cytokines/chemokines or their receptor genes. Changes in *ADAM17* expression were correlated with changes in most of the innate immune response genes that were examined, including inflammatory cytokines/chemokines. Together with the WGCNA gene co-expression analysis, these findings show that the expression levels of SARS-CoV-2-related genes are closely related to those of innate immune response genes, suggesting they may share common transcriptional regulation that is modified by ICS.

Discussion

To our knowledge, this is the first prospective RCT in patients with COPD to report the effects of ICS on SARS-CoV-2-related gene expression. We showed that 12 weeks of treatment with combination LABA/ICS (compared to LABA monotherapy) resulted in a significant reduction in the expression of the SARS-CoV-2 receptor gene *ACE2* and the host cell protease gene *ADAM17* in the airway mucosa of COPD patients. Using network analysis, we also showed that *ACE2*, *ADAM17* and the host cell protease gene *FURIN* were co-expressed with genes involved in the innate

immune response and that, qualitatively, these co-expressed genes were also downregulated by ICS therapy. Finally, we showed that changes in the expression of SARS-CoV-2-related genes were correlated with changes in expression of innate immune genes, particularly those of the IFN-I pathway. These results provide an insight into the complex changes induced by ICS in the respiratory epithelium that might impact on the risk of COVID-19 or its outcomes in patients with COPD.

Previous studies suggest that corticosteroid use is associated with an increased risk of infection with common respiratory virus and impaired viral clearance (21). There is also a well-documented association between ICS use and increased risk of pneumonia in COPD (2), which naturally raises concerns that ICS use may be harmful in COPD patients with COVID-19. On the other hand, several findings point towards a potential protective effect of corticosteroids in COVID-19. For example, asthma is more commonly treated with ICS but, unlike COPD, is not associated with increased risk of severe COVID-19 (23). A recent RCT found that systemic dexamethasone treatment improved mortality in severe COVID-19 patients who were mechanically ventilated (24). Additionally, the ICS ciclesonide has been shown to inhibit SARS-CoV-2 replication *in vitro* (25). However, a recent analysis of 148,488 COPD patients in the United Kingdom found no significant association between ICS therapy and COVID-19 severity or mortality (4). Current international consensus statements recommend that patients continue their current COPD medications until further evidence comes to hand (26).

SARS-CoV-2 achieves host cell entry primarily via membrane-bound ACE2. We previously showed that *ACE2* gene and protein expression was increased in the

bronchial epithelium (6) and lung tissue (7) of people with COPD, a finding confirmed by other investigators (27, 28). Increased availability of ACE2 may increase the susceptibility to infection and the risk of severe COVID-19 (29, 30). In the present study, *ACE2* expression increased after 12 weeks of formoterol monotherapy, but in the absence of a placebo arm it is unclear if this represents an effect of the intervention or some other driving force. Nevertheless, the addition of ICS in the form of FOR/BUD and SAL/FLU significantly attenuated this increase, suggesting that ICS is active in the regulation of *ACE2* expression. If high expression of *ACE2* increases the susceptibility of cells to SARS-CoV-2 infection, then downregulation by ICS should, in theory, be protective. However, since ACE2 is a critical counter-regulator of the renin-angiotensin-aldosterone system, its downregulation may predispose to angiotensin-II/AT1-mediated acute lung injury (ALI). This phenomenon has been demonstrated in *Ace2* knockout mouse models of aspiration-, sepsis- and SARS-CoV-induced ALI (31, 32).

Current evidence suggests that *ACE2* expression is intrinsically linked to the activity of IFN-I. Recently, Ziegler et al (33) showed that ACE2 expression in primary nasal epithelial cells was induced by IFN-alpha, suggesting *ACE2* is an interferon-stimulated gene (ISG) in epithelial cells. Our results support this hypothesis in two ways: first, using WGCNA, we found that *ACE2* co-expressed genes were highly enriched with genes involved in the IFN-I pathway; and second, the changes in *ACE2* induced by ICS were highly correlated with changes in other ISGs such as *OAS2/3*, *CXCL10*, and *RSAD2* (34). The IFN-I pathway is critical in the early cellular response to viral infection, acting as a 'first alarm' by inducing the expression of ISGs (which create an anti-viral state within the cell) and pro-inflammatory cytokines (34). The

function of *ACE2* as an ISG is unknown, but its induction by IFN-I may serve to counteract any accompanying angiotensin-II/AT1-mediated lung inflammation following viral infection.

Coronaviruses have a particular ability to evade the IFN response, which allows efficient and rapid viral replication (35). However, outcomes for the host may depend on the extent and timing of the IFN response mounted. In a murine model of SARS-CoV infection, Channappanavar et al (36) showed that a robust early IFN response limited viral replication and prevented excessive lung damage, while a robust but delayed IFN response was associated with excessive inflammation and death. Interestingly, a muted or absent IFN-I response was associated with minimal lung damage despite high viral titers (36) highlighting the potential pathogenic role of the IFN-I response. Other recent studies support the hypothesis that IFNs contribute to COVID-19 pathology (37, 38). Zhuang et al recently determined that SARS-CoV-2 can positively induce *ACE2* expression, most likely by activating IFN-I pathways (39). We speculate that *ACE2* upregulation by IFNs may result in a feed-forward cycle whereby the anti-viral response of epithelial cells actually enhances their susceptibility to SARS-CoV-2 infection. Thus the IFN response to SARS-CoV-2 may be a two-edged sword: an early and appropriately-regulated IFN response may inhibit the virus and cause minimal symptoms, whereas a delayed or dysregulated IFN response may facilitate viral replication, dissemination, and excessive inflammation leading to severe COVID-19. Consistent with this hypothesis, recent studies in people with COVID-19 support a role for treatment with IFN-I if administered early in the clinical course (40, 41). COPD patients already have impaired IFN-I responses following viral infection (42), meaning this patient

population may be particularly susceptible to severe COVID-19 by this mechanism and thus candidates for targeted, early IFN treatment.

ICS may therefore affect COVID-19 outcomes by modifying IFN signaling in the airway epithelium. *In vitro* studies have shown that corticosteroids decrease IFN-I expression (21, 43). However, consistent with previous findings in COPD, the expression levels of these genes in our BEC samples were extremely low and therefore we cannot confirm any treatment effect. Regardless, how ICS treatment affects the magnitude and timing of the IFN-I responses following viral infection may be more important, and this should be the focus of future investigations.

We also showed that LABA/ICS therapy significantly downregulated BEC expression of *ADAM17*. The viral S protein induces ADAM17-dependent shedding of the ACE2 ectodomain, creating the soluble form of ACE2 and facilitating fusion of the viral and cell membranes (44). Inhibition of ADAM17 at least partially blocks SARS-CoV entry in cultured epithelial cells (12, 44), highlighting this protease as a potential therapeutic target. ADAM17 also plays a crucial role in interleukin-6 (IL-6) signaling, which is activated in severe COVID-19 (45). Shedding of the IL-6 receptor (IL-6R) ectodomain facilitates a pro-inflammatory response via the so-called *trans*-signaling IL-6 pathway (46), and selective blockade of IL-6 *trans*-signaling can attenuate sepsis in mice (47). ADAM17 has therefore been described as a “master switch” between the pro-inflammatory *trans*- and anti-inflammatory *classical*- (i.e. via membrane-bound IL-6R) IL-6 signaling pathways (48). However, since inhibitors of ADAM17 have not been successful in clinical trials of inflammatory diseases (49), a

beneficial effect of *ADAM17* downregulation by ICS on COVID-19 outcomes is, at this time, speculative.

There are several limitations to our study. First, the relatively small sample size may explain why there were many non-significant trends in pre- to post-treatment change in gene expression. However, the largely consistent directions of change between ICS treatment arms suggests these effects were not due to chance alone. Second, we do not have longer-term follow-up gene expression data to know if the observed changes are durable. Third, we enrolled only stable participants so cannot know if ICS alters the expression of these genes during unstable periods. Fourth, we studied gene rather than protein expression and so cannot necessarily infer changes in protein levels or function. Finally, our data were derived from BECs rather than alveolar or endothelial cells, and may not directly reflect the risk of SARS-CoV-2 infection or ALI in the lung.

Our results show that ICS medications have activity on the expression of key SARS-CoV-2 related genes in COPD patients, and that expression of the SARS-CoV-2 receptor gene *ACE2* is closely related to the expression of anti-viral IFN-I pathways. Whether this translates into altered COVID-19 outcomes requires further study: there are at least two RCTs currently underway (clinicaltrials.gov identifiers NCT04381364 and NCT04355637) which may shed some light. Ultimately, optimal control of COPD symptoms and exacerbation risk may be the most important determinants of clinical outcomes in these patients. For this reason, we agree with the international consensus that ICS use in COPD patients should be continued if clinically indicated until further evidence is available.

Methods

Comprehensive methods are presented in the Online Data Supplement.

Design of the DISARM trial

The DISARM study aimed to determine the effects of ICS on the lung microbiome in COPD. The full trial protocol is registered at clinicaltrials.gov (NCT02833480) and the study was approved by the Human Research Ethics Committee of the University of British Columbia and Providence Health Care (H14-02277). After providing written informed consent, enrolled participants with mild to very severe COPD went through an initial 4-week run-in period with FOR plus short-acting beta-agonist (SABA) as required followed by a baseline bronchoscopy. They were then randomized to receive ongoing LABA monotherapy with FOR, or LABA/ICS combination therapy with FOR/BUD or SAL/FLU for 12 weeks, followed by a second bronchoscopy. At each bronchoscopy, bronchial brushes (6-8th generation airway) and bronchoalveolar lavage (right middle lobe or lingula) were collected from sites away from any pathology identified on CT scan. Bronchoscopists and laboratory personnel were blinded to treatment assignment.

Sample processing, RNA extraction and RNA sequencing

RNA was extracted from cytological brush specimens stored in QIAzol RNA lysis buffer (QIAGEN, Stockach, Germany) using the RNeasy Plus kit (QIAGEN) and sample quality control was performed using the Agilent 2100 Bioanalyzer (Agilent,

Santa Clara, CA, USA). RNA sequencing was performed on the Illumina NextSeq 500 (Illumina, San Diego, CA, USA) with paired end 42bp-by-42bp reads. RNA-seq data is available at [add prior to publication].

Bioinformatics and statistical comparisons

Quality control of raw sequencing reads, alignment, and count normalization procedures are described in the Online Data Supplement. Principal component analysis was used to visualize data, in order to exclude any between-group baseline differences in gene expression. The Weighted Gene Co-expression Network Analysis (WGCNA) package in R (17, 18) was used to identify modules of co-expressed genes. Gene functional enrichment analyses were performed using WebGestaltR (50).

ACKNOWLEDGEMENTS:

The authors acknowledge the volunteers who participated in the DISARM trial, and Mr. Ryan vander Werff at UBC Biomedical Research Centre for conducting and advising on RNA sequencing. The authors would like to thank Mr. Irving Ding and Mrs. Chun Hong Tao for their financial support of the St Paul's Foundation COVID-19 Response Fund. SFvE is the Canadian Institute for Health Research/Glaxo Smith Kline (CIHR/GSK) Professor in Chronic Obstructive Pulmonary Disease. DDS holds the De Lazzari Family Chair at HLI and is a Tier 1 Canada Research Chair in COPD.

REFERENCES:

1. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, Liu XQ, Chen RC, Tang CL, Wang T, Ou CQ, Li L, Chen PY, Sang L, Wang W, Li JF, Li CC, Ou LM, Cheng B, Xiong S, Ni ZY, Xiang J, Hu Y, Liu L, Shan H, Lei CL, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Cheng LL, Ye F, Li SY, Zheng JP, Zhang NF, Zhong NS, He JX, China Medical Treatment Expert Group for C. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020; 55: 2000547.
2. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2014: CD010115.
3. Davies JM, Carroll ML, Li H, Poh AM, Kirkegard D, Towers M, Upham JW. Budesonide and formoterol reduce early innate anti-viral immune responses in vitro. *PLoS One* 2011; 6: e27898.
4. Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson EJ, Drysdale H, Croker R, Bacon S, Hulme WJ, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Evans SJW, Quint J, Smeeth L, Douglas IJ, Goldacre B. Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis. *medRxiv* 2020: 2020.2006.2019.20135491.
5. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. *Eur Respir J* 2020; 55: 2001009.

6. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, Dorscheid DR, Sin DD.
ACE-2 expression in the small airway epithelia of smokers and COPD patients:
implications for COVID-19. *Eur Respir J* 2020; 55: 2000688.
7. Milne S, Yang CX, Timens W, Bosse Y, Sin DD. SARS-CoV-2 receptor ACE2 gene expression
and RAAS inhibitors. *Lancet Respir Med* 2020; 8: e50-e51.
8. Finney LJ, Glanville N, Farne H, Aniscenko J, Fenwick P, Kemp SV, Trujillo-Torralbo M-B,
Calderazzo MA, Wedzicha JA, Mallia P, Bartlett NW, Johnston SL, Singanayagam A.
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD
through suppression of type I interferon. *bioRxiv* 2020: 2020.2006.2013.149039.
9. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG,
Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie
AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy
JV. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic
Features and Corticosteroids. *Am J Respir Crit Care Med* 2020; 202: 83-90.
10. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens
TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
Inhibitor. *Cell* 2020; 181: 271-280 e278.
11. Wang K, Chen W, Zhou Y-S, Lian J-Q, Zhang Z, Du P, Gong L, Zhang Y, Cui H-Y, Geng J-J,
Wang B, Sun X-X, Wang C-F, Yang X, Lin P, Deng Y-Q, Wei D, Yang X-M, Zhu Y-M,
Zhang K, Zheng Z-H, Miao J-L, Guo T, Shi Y, Zhang J, Fu L, Wang Q-Y, Bian H, Zhu P,
Chen Z-N. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.
bioRxiv 2020: 2020.2003.2014.988345.

12. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. *J Virol* 2014; 88: 1293-1307.
13. Follis KE, York J, Nunberg JH. Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell-cell fusion but does not affect virion entry. *Virology* 2006; 350: 358-369.
14. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral Res* 2020; 176: 104742.
15. Barnes PJ. Corticosteroid effects on cell signalling. *Eur Respir J* 2006; 27: 413-426.
16. van Dam S, Vosa U, van der Graaf A, Franke L, de Magalhaes JP. Gene co-expression analysis for functional classification and gene-disease predictions. *Brief Bioinform* 2018; 19: 575-592.
17. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. *Stat Appl Genet Mol Biol* 2005; 4: Article17.
18. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* 2008; 9: 559.
19. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W,

- Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R, Gene Ontology C. The Gene Ontology (GO) database and informatics resource. *Nucleic Acids Res* 2004; 32: D258-261.
20. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res* 1999; 27: 29-34.
21. Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, Toussaint M, Walton RP, Finney LJ, Aniscenko J, Zhu J, Trujillo-Torralbo MB, Calderazzo MA, Grainge C, Loo SL, Veerati PC, Pathinayake PS, Nichol KS, Reid AT, James PL, Solari R, Wark PAB, Knight DA, Moffatt MF, Cookson WO, Edwards MR, Mallia P, Bartlett NW, Johnston SL. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. *Nat Commun* 2018; 9: 2229.
22. Skevaki CL, Christodoulou I, Spyridaki IS, Tiniakou I, Georgiou V, Xepapadaki P, Kafetzis DA, Papadopoulos NG. Budesonide and formoterol inhibit inflammatory mediator production by bronchial epithelial cells infected with rhinovirus. *Clin Exp Allergy* 2009; 39: 1700-1710.
23. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, Mai Q, Yeh C, Muhammad LN, Harris KE, Bochner BS, Grammer LC, Greenberger PA, Kalhan R, Kuang FL, Saltoun CA, Schleimer RP, Stevens WW, Peters AT. Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19. *J Allergy Clin Immunol* 2020.
24. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak

- E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med* 2020.
25. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. *bioRxiv* 2020: 2020.2003.2011.987016.
26. Global Initiative for Chronic Obstructive Lung Disease. GOLD COVID-19 GUIDANCE. 2020. Available from: <https://goldcopd.org/gold-covid-19-guidance/>.
27. Zhang H, Rostami MR, Leopold PL, Mezey JG, O'Beirne SL, Strulovici-Barel Y, Crystal RG. Expression of the SARS-CoV-2 ACE2 Receptor in the Human Airway Epithelium. *Am J Respir Crit Care Med* 2020; 202: 219-229.
28. Jacobs M, Van Eeckhoutte HP, Wijnant SRA, Janssens W, Joos GF, Brusselle GG, Bracke KR. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. *Eur Respir J* 2020: 2002378.
29. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. *Biochem Biophys Res Commun* 2004; 319: 1216-1221.
30. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Thurmann L, Kurth F, Volker MT, Kazmierski J, Timmermann B, Twardziok S, Schneider S, Machleidt F, Muller-Redetzky H, Maier M, Krannich A, Schmidt S, Balzer F, Liebig J, Loske J, Suttorp N, Eils J, Ishaque N, Liebert UG, von Kalle C, Hocke A, Witzenrath M, Goffinet C, Drosten C, Laudi S, Lehmann I, Conrad C, Sander LE, Eils R. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. *Nat Biotechnol* 2020.

31. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 2005; 436: 112-116.
32. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 2005; 11: 875-879.
33. Ziegler CGK, Allon SJ, Nyquist SK, Mbanjo IM, Miao VN, Tzouanas CN, Cao Y, Yousif AS, Bals J, Hauser BM, Feldman J, Muus C, Wadsworth MH, 2nd, Kazer SW, Hughes TK, Doran B, Gatter GJ, Vukovic M, Taliaferro F, Mead BE, Guo Z, Wang JP, Gras D, Plaisant M, Ansari M, Angelidis I, Adler H, Sucre JMS, Taylor CJ, Lin B, Waghray A, Mitsialis V, Dwyer DF, Buchheit KM, Boyce JA, Barrett NA, Laidlaw TM, Carroll SL, Colonna L, Tkachev V, Peterson CW, Yu A, Zheng HB, Gideon HP, Winchell CG, Lin PL, Bingle CD, Snapper SB, Kropski JA, Theis FJ, Schiller HB, Zaragosi LE, Barbry P, Leslie A, Kiem HP, Flynn JL, Fortune SM, Berger B, Finberg RW, Kean LS, Garber M, Schmidt AG, Lingwood D, Shalek AK, Ordovas-Montanes J, lung-network@humancellatlas.org HCALBNEa, Network HCALB. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell* 2020; 181: 1016-1035 e1019.
34. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. *Annu Rev Immunol* 2014; 32: 513-545.

35. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol* 2017; 39: 529-539.
36. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe* 2016; 19: 181-193.
37. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, Choi B, Nam SK, Sa M, Kwon JS, Jeong SJ, Lee HK, Park SH, Park SH, Choi JY, Kim SH, Jung I, Shin EC. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. *Sci Immunol* 2020; 5: eabd1554.
38. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M, Wang J. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe* 2020; 27: 883-890 e882.
39. Zhuang MW, Cheng Y, Zhang J, Jiang XM, Wang L, Deng J, Wang PH. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection. *J Med Virol* 2020; n/a.
40. Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, Qian X, Wang S, Guo Y, Yu H, Cui M, Tong G, Xu Y, Zheng Z, Lu Y, Hong P. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. *Cell Host Microbe* 2020.
41. Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC,

- Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* 2020; 395: 1695-1704.
42. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebabdz T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. *Am J Respir Crit Care Med* 2011; 183: 734-742.
43. Flammer JR, Dobrovolna J, Kennedy MA, Chinenov Y, Glass CK, Ivashkiv LB, Rogatsky I. The type I interferon signaling pathway is a target for glucocorticoid inhibition. *Mol Cell Biol* 2010; 30: 4564-4574.
44. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Yamamoto N, Sasazuki T, Ishizaka Y. Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. *Proc Natl Acad Sci U S A* 2008; 105: 7809-7814.
45. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* 2020; 20: 363-374.
46. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta* 2011; 1813: 878-888.
47. Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, Mueller-Heine A, Chalaris A, Scheller J, Rose-John S, Seegert D, Krettek C, Waetzig

- GH. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. *Crit Care Med* 2011; 39: 1407-1413.
48. Mahmud-Al-Rafat A, Majumder A, Taufiqur Rahman KM, Mahedi Hasan AM, Didarul Islam KM, Taylor-Robinson AW, Billah MM. Decoding the enigma of antiviral crisis: Does one target molecule regulate all? *Cytokine* 2019; 115: 13-23.
49. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. *Nat Clin Pract Rheumatol* 2008; 4: 300-309.
50. Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res* 2019; 47: W199-W205.

FIGURE LEGENDS:

Figure 1: CONSORT flow chart for the DISARM trial. Run-in period comprised 4 weeks treatment with formoterol (FOR) 12 µg inhaled twice daily via Turbuhaler. Randomization was in 1:1:1 ratio in blocks of 6, stratified by prior history of inhaled corticosteroid use. Treatment was open-label with FOR 12 µg inhaled twice daily via Turbuhaler, formoterol/budesonide (FOR/BUD) combination 12/400 µg inhaled twice daily via Turbuhaler, or salmeterol/fluticasone propionate (SAL/FLU) 50/250 µg inhaled twice daily via Diskus, for 12 weeks.

Figure 2: Baseline (pre-treatment) bronchial epithelial cell expression of SARS-CoV-2-related genes in COPD. Total samples n=61 (two out of the 63 randomized participants had insufficient RNA for sequencing). (A) Each of the 5 key SARS-CoV-2-related genes were expressed at baseline. (B) Increasing age was associated with decreasing expression of *ACE2* and *BSG*. P value from linear regression (C) Current smokers had significantly greater expression of *ACE2*, *BSG* and *TMPRSS2* genes compared to ex-smokers. p value from Wilcoxon rank-sum test. Abbreviations: TPM, transcripts per million; CPM, counts per million.

Figure 3: Pre- to post-treatment change in bronchial epithelial cell gene expression ($\Delta\log_2\text{CPM}$). Total n=54 participants had both pre- and post-treatment RNA sequencing data available. Compared to treatment with FOR alone, FOR/BUD and SAL/FLU treatment significantly decreased expression of the SARS-CoV-2 receptor gene *ACE2* (A), and FOR/BUD treatment significantly decreased expression of the host cell protease gene *ADAM17* (B). Between-group comparisons are by

Wilcoxon rank-sum test. Abbreviations: FOR, formoterol; BUD, budesonide; SAL, salmeterol; FLU, fluticasone propionate; CPM, counts per million; ns, non-significant.

* $p < 0.05$ *** $p < 0.001$.

Figure 4: Heat map of pre- to post-treatment change in gene expression

($\Delta \log_2 \text{CPM}$) across the transcriptome. Each column represents a single gene (total 1,188 genes, selected for plotting based on between-group pairwise Wilcoxon rank-sum test at $\text{FDR} < 0.05$). Treatment with FOR/BUD and SAL/FLU tended to decrease the expression of genes belonging to the *ACE2* and *ADAM17/FURIN* co-expression modules. Genes are arranged using hierarchical clustering. Each gene is annotated by membership of one of the SARS-CoV-2-related gene co-expression modules. Abbreviations: FOR, formoterol; BUD, budesonide; SAL, salmeterol; FLU, fluticasone propionate; CPM, counts per million.

Figure 5: Weighted gene correlation network analysis. This methodology identifies clusters or modules of highly-connected genes. The 5 key SARS-CoV-2-related genes were found in 3 modules, represented by colors. ‘Size’ is number of genes connected to the module eigengene at false discovery rate < 0.05 . ‘Hub gene’ has the strongest module membership (i.e. strongest correlation with the module eigengene). Listed are the 20 genes with the strongest connection (based on the weighted topological overlap matrix) to the relevant SARS-CoV-2-related gene. See Zhang and Horvath (17) for full description of the WGCNA methodology and terminology.

Figure 6: Gene Ontology (GO) biological process enrichment in SARS-CoV-2-related gene co-expression modules. Top 20 GO processes by FDR are shown, ordered by % overlapping genes (proportion of genes in the GO process that also appear in the gene module). The *ACE2* module (A) was highly enriched with genes related to the response to interferons and response to virus. The *ADAM17/FURIN* module (B) was enriched with genes related to regulation of innate immunity, leukocyte function, and cytokine production. The *BSG/TMPRSS2* module (C) was enriched for genes related to cellular functions including nucleic acid processing. Abbreviations: FDR, false discovery rate.

Figure 7: Change in selected innate immune response genes following treatment. (A) Heat map of pre- to post-treatment change in gene expression ($\Delta\log_2\text{CPM}$) of innate immune response genes. FOR/BUD and SAL/FLU treatment tended to decrease the expression of the innate immune response genes. *FDR<0.05 for pre- to post-treatment Wilcoxon signed rank test. (B) Pearson correlation of change in expression ($\Delta\log_2[\text{TPM}+1]$) of immune response genes with change in expression of key SARS-CoV-2-related genes following LABA/ICS treatment (FOR/BUD and SAL/FLU groups combined). Changes in *ACE2* expression were highly correlated with changes in IFN-I/III signal transducers, viral sensors and ISGs. Only correlations with FDR <0.1 are shown. Abbreviations: FOR, formoterol; BUD, budesonide; SAL, salmeterol; FLU, fluticasone propionate; CPM, counts per million; TPM, transcripts per million; IFN-I/III, type I and III interferons; ISGs, interferon stimulated genes

LEGENDS FOR FIGURES APPEARING IN ONLINE SUPPLEMENT:

Figure E1: Principal component analysis (PCA) of baseline whole-transcriptome gene expression data. PCA plot grouped by treatment group (n=61 participants with pre-treatment sequencing data available) shows no obvious separation, suggesting that pre-treatment gene expression was similar between groups. Only genes passing quality control filtering were analyzed.

Figure E2: Pre- to post-treatment change in expression ($\Delta\log_2\text{CPM}$) of key SARS-CoV-2-related genes. (A) *ACE2*, (B) *BSG*, (C) *TMPRSS2*, (D) *ADAM17*, (E) *FURIN*. Boxplots show median and interquartile range. P value from Wilcoxon signed rank test. Abbreviations: CPM, counts per million.

Figure E3: Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment in SARS-CoV-2-related gene co-expression modules. Top 20 KEGG pathways by FDR are shown, ordered by % overlapping genes (proportion of genes in the KEGG pathway that also appear in the gene module). The *ACE2* module (A) was enriched with genes related to viral diseases including influenza A and measles, as well as disorders of the immune system including primary immunodeficiency and allograft rejection. The *ADAM17/FURIN* module (B) was enriched with genes related to bacterial diseases including leishmaniasis and *Staphylococcus aureus* infection, as well as the autoimmune disease rheumatoid arthritis. The *BSG/TMPRSS2* module

(C) was not enriched for any human disease pathways at $FDR < 0.05$. Abbreviations: FDR, false discovery rate.

Figure E4: Scatter plots showing correlation of pre- to post-treatment change in selected immune response genes with change in key SARS-CoV-2-related genes for LABA/ICS treatment groups combined. Pre- to post-treatment change quantified as $\Delta \log_2(TPM+1)$. r from Pearson correlation. Top 3 correlated innate immune response genes for each SARS-CoV-2-related gene shown: (A) *ACE2*, (B) *ADAM17*, (C) *FURIN*, (D) *TMPRSS2*. There were no correlations with change in *BSG* at $FDR < 0.05$.

TABLES:

	Treatment arm		
	FOR	FOR/BUD	SAL/FLU
Participants, n	21	20	22
Male sex, n (%)	18 (86)	17 (85)	17 (77)
Age, median (IQR) years	63 (55 - 68)	66 (63 - 70)	66 (60 - 72)
BMI, median (IQR) kg/m ²	24.30 (21.19 - 30.56)	23.87 (20.28 - 27.22)	27.25 (23.01 - 30.43)
Current smoker, n (%)	11 (52)	7 (35)	11 (50)
Hypertension, n (%)	5 (24)	6 (30)	4 (21)
Obesity [†] , n (%)	6 (29)	4 (20)	6 (27)
FEV ₁ , median (IQR) %predicted	64.5 (50 - 73)	58.0 (48.1 - 74.5)	58.0 (45.8 - 73)
FEV ₁ /FVC, median (IQR) %	56.1 (45.3 - 62.8)	49.0 (44.6 - 61.5)	52.3 (48.8 - 64.4)
GOLD stage I/II, n (%)	13 (62)	11 (55)	12 (55)
GOLD stage III/IV, n (%)	8 (38)	9 (45)	10 (45)
Respiratory medications			
LAMA, n (%)	19 (91)	19 (95)	16 (73)
Methylxanthines, n (%)	0 (0)	1 (5)	0 (0)
Health status (SGRQ)			
Symptom domain	44.5 (23.5)	47.5 (19.8)	49.9 (26.3)
Activity domain	61.1 (13)	60.3 (27.8)	58.9 (19.1)
Impact domain	29.5 (15.8)	26.6 (15.9)	26.0 (20.2)
Total score	41.7 (14.8)	39.4 (17.6)	39.7 (19.2)
Peripheral blood cells			
White blood cells (x10 ⁹ /mL)	7.92 (2.24)	6.80 (2.35)	7.73 (1.77)
Neutrophils (x10 ⁹ /mL)	5.12 (1.86)	4.46 (1.83)	4.41 (1.12)
Eosinophils (x10 ⁹ /mL)	0.24 (0.12)	0.24 (0.15)	0.27 (0.11)

Table 1: Characteristics of randomized participants in the DISARM trial. Data are mean (SD) unless otherwise indicated. [†]obesity defined as BMI≥30 kg/m².

Abbreviations: FOR, formoterol; BUD, budesonide; SAL, salmeterol; FLU, fluticasone propionate; IQR, interquartile range; BMI, body mass index; FEV₁, forced expiratory

volume in 1 second; FVC, forced vital capacity; LAMA, long-acting muscarinic antagonist; SGRQ, St George's Respiratory Questionnaire.

Run-in (4 weeks)

Participants enrolled (n=89)

6 excluded
3 ischemic heart disease (IHD)
3 became medically unstable
18 withdrew prior to bronchoscopy
4 withdrew consent
12 missed attendance
1 increased symptoms during run-in
1 adverse reaction during run-in

Baseline bronchoscopy (n=65)

2 withdrew prior to randomization
2 withdrew consent

Randomization (n=63)

Treatment (12 weeks)

Formoterol (FOR)
(n=21)

1 did not complete trial
1 missed attendance

**Post-treatment
bronchoscopy (n=20)**

Formoterol/budesonide
(FOR/BUD) (n=20)




2 did not complete trial
1 withdrew consent
1 required surgery



**Post-treatment
bronchoscopy (n=18)**

Salmeterol/fluticasone
(SAL/FLU) (n=22)


4 did not complete trial
1 IHD
1 adverse reaction
2 missed attendance

**Post-treatment
bronchoscopy (n=18)**

A**B****C**

A**B**

medRxiv preprint doi: <https://doi.org/10.1101/2020.08.19.20178368>; this version posted August 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



FURIN

GNA13	MTMR14
PLEKHO2	GMIP
ITPRIP	PPP1R18
CXCL16	PTPRE
FAM49B	ARHGAP30
ARID5A	LRRC25
RAB8B	VASP
RHOG	ARRB2
AKIRIN2	SIRPA
MYD88	ATP6V1B2

Size:
2,091 genes
Hub gene:
GNA13

ADAM17

GNA13	SIRPA
PLEKHO2	FAM49B
ARID5A	CXCL16
ARHGAP30	PPP1R18
PTPRE	SH3BP2
ITPRIP	MTMR14
ARHGAP30	GMIP
LRRC25	STX4
PPP1R18	RNF149

ACE2

Size: 538 genes
Hub gene: DDX58

DTX3L	SQOR
PLSCR1	ZNFX1
OAS3	IFIT2
NMI	LGALS9
TRIM21	SAMD9L
TRIM38	SAMD9
IFIH1	ATF5
DDX58	PML
IFI35	HELZ2
TRAFD1	APOL2




TMPRSS2



MFSD6	ICMT
AASDHPPT	HTATSF1
ZMYND11	DLAT
RPRD1A	MYO1D
SSRP1	NBR1
FOXA1	SYPL1
OSBP	CMTM4
UBE2G1	TOB2
IARS2	PEX5
TSPYL1	RNF20


Size:
1528 genes
Hub gene:
AASDHPPT

BSG

OSBP	HTATSF1
NOP9	NBR1
MFSD6	CCT7
CAPRN1	TSPYL1
AASDHPPT	SSRP1
TCP1	EIF4H
UBE2G1	CSTF2T
DLAT	PDAP1
ICMT	TEX261
YWHAQ	MYO1D



A**B**



—●— FOR —●— FOR/BUD —●— SAL/FLU

